Venus Medtech cooperates with New Frontier Health/United Family Healthcare to establish diagnosis and treatment centers for valvular heart disease

On December 6th, 2021, Venus Medtech (Hangzhou) Inc. ("Venus Medtech", 2500.HK), China’s leading provider of integrated solutions for interventional valvular heart disease treatment, announced strategic cooperation framework agreement with United Family Healthcare (“UFH”), a leading premium private healthcare service provider under New Frontier Health Corporation. The parties will pool their respective capabilities and advantages to explore new cooperation models for medical services, and establish pilot cooperation sites and specialist centers for the diagnosis and treatment of valvular heart disease.

According to the Agreement, the Company will cooperate with UFH to establish a diagnosis and treatment cooperation pilot for aortic valve replacement, Venus A-Valve and Venus A-Plus, and both parties will work jointly on the establishment of the valvular heart disease specialist center in the field of disease diagnosis and treatment and postoperative rehabilitation management, so as to better provide patients with the best diagnosis and treatment scheme worldwide. A joint steering committee will be established by both parties to determine the daily operation of the specialist center.

UFH, a member of New Frontier Health Corporation, is one of the largest and best recognized comprehensive premium private healthcare providers in China. UFH offers a complete suite of international-standard healthcare services, covering preventive care, diagnosis, treatment, and rehabilitation. UFH enjoys a network of 9 comprehensive and specialty hospitals and 16 satellite clinics (in operation or under construction) in all first-tier cities and selected second-tier cities, and a nationwide internet hospital.

Taking root in China and embracing global opportunities, Venus Medtech is a developer, manufacturer, and marketer of medical devices for valvular heart disease, aiming at developing innovative products with high clinical values and continuously popularizing the clinical use of innovative therapies. The company has started a new chapter for TAVR in China with high-quality products and superior service. Moving forward, it will continue efforts to introduce and develop pioneering devices for structural heart disease unprecedented in the country.


Eric Zi, Founder, Chief Executive Officer and General Manager of Venus Medtech said “This cooperation will enable us to give full play to our respective advantages to popularize and optimize interventional treatment for heart valve diseases by virtue of the UFH platform. We look to expand the clinical use of our products and explore cooperation in commercial insurance, which speaks to our long-term development in strategic ways.”

Wu Qi’nan, President of New Frontier Health Corporation/United Family Healthcare, said "UFH has been committed to providing patients with high-quality and personalized diagnosis and treatment services since day one, with continuously increasing investment in medical technology and equipment. The partnership with Venus Medtech, the first company to launch NMPA-approved TAVR products nationwide, will contribute to the adoption of innovative valvular heart disease treatment devices in private hospital systems. We believe the new cooperation model will maximize the advantages of both sides and bring premium quality medical services to more doctors and patients.”

Prev:Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral ···

Next:Venus Medtech Wins 2021 Corporate Public Welfare Contribution Pioneer Award